Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex - PubMed (original) (raw)
Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex
W R Tulip et al. J Mol Biol. 1992.
Abstract
The crystal structure of the complex between neuraminidase from influenza virus (subtype N9 and isolated from an avian source) and the antigen-binding fragment (Fab) of monoclonal antibody NC41 has been refined by both least-squares and simulated annealing methods to an R-factor of 0.191 using 31,846 diffraction data in the resolution range 8.0 to 2.5 A. The resulting model has a root-mean-square deviation from ideal bond-length of 0.016 A. One fourth of the tetrameric complex comprises the crystallographic model, which has 6577 non-hydrogen atoms and consists of 389 protein residues and eight carbohydrate residues in the neuraminidase, 214 residues in the Fab light chain, and 221 residues in the heavy chain. One putative Ca ion buried in the neuraminidase, and 73 water molecules, are also included. A remarkable shape complementarity exists between the interacting surfaces of the antigen and the antibody, although the packing density of atoms at the interface is somewhat looser than in the interior of a protein. Similarly, there is a high degree of chemical complementarity between the antigen and antibody, mediated by one buried salt-link, two solvated salt-links and 12 hydrogen bonds. The antibody-binding site on neuraminidase is discontinuous and comprises five chain segments and 19 residues in contact, whilst 33 neuraminidase residues in eight segments have 899 A2 of surface area buried by the interaction (to a 1.7 A probe), including two hexose units. Seventeen residues in NC41 Fab lying in five of the six complementarity determining regions (CDRs) make contact with the neuraminidase and 36 antibody residues in seven segments have 916 A2 of buried surface area. The interface is more extensive than those of the three lysozyme-Fab complexes whose crystal structures have been determined, as judged by buried surface area and numbers of contact residues. There are only small differences (less than 1.5 A) between the complexed and uncomplexed neuraminidase structures and, at this resolution and accuracy, those differences are not unequivocal. The main-chain conformations of five of the CDRs follow the predicted canonical structures. The interface between the variable domains of the light and heavy chains is not as extensive as in other Fabs, due to less CDR-CDR interaction in NC41. The first CDR on the NC41 Fab light chain is positioned so that it could sterically hinder the approach of small as well as large substrates to the neuraminidase active-site pocket, suggesting a possible mechanism for the observed inhibition of enzyme activity by the antibody.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
- Crystal structures of two mutant neuraminidase-antibody complexes with amino acid substitutions in the interface.
Tulip WR, Varghese JN, Webster RG, Laver WG, Colman PM. Tulip WR, et al. J Mol Biol. 1992 Sep 5;227(1):149-59. doi: 10.1016/0022-2836(92)90688-g. J Mol Biol. 1992. PMID: 1522584 - Three-dimensional structures of the free and antigen-bound Fab from monoclonal antilysozyme antibody HyHEL-63(,).
Li Y, Li H, Smith-Gill SJ, Mariuzza RA. Li Y, et al. Biochemistry. 2000 May 30;39(21):6296-309. doi: 10.1021/bi000054l. Biochemistry. 2000. PMID: 10828942 - N9 neuraminidase complexes with antibodies NC41 and NC10: empirical free energy calculations capture specificity trends observed with mutant binding data.
Tulip WR, Harley VR, Webster RG, Novotny J. Tulip WR, et al. Biochemistry. 1994 Jul 5;33(26):7986-97. doi: 10.1021/bi00192a002. Biochemistry. 1994. PMID: 7517697 - Interactions of protein antigens with antibodies.
Davies DR, Cohen GH. Davies DR, et al. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):7-12. doi: 10.1073/pnas.93.1.7. Proc Natl Acad Sci U S A. 1996. PMID: 8552677 Free PMC article. Review. - The structural basis of antigen-antibody recognition.
Mariuzza RA, Phillips SE, Poljak RJ. Mariuzza RA, et al. Annu Rev Biophys Biophys Chem. 1987;16:139-59. doi: 10.1146/annurev.bb.16.060187.001035. Annu Rev Biophys Biophys Chem. 1987. PMID: 2439094 Review.
Cited by
- Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.
Creytens S, Pascha MN, Ballegeer M, Saelens X, de Haan CAM. Creytens S, et al. Front Immunol. 2021 Nov 16;12:786617. doi: 10.3389/fimmu.2021.786617. eCollection 2021. Front Immunol. 2021. PMID: 34868073 Free PMC article. Review. - Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase.
Lei R, Kim W, Lv H, Mou Z, Scherm MJ, Schmitz AJ, Turner JS, Tan TJC, Wang Y, Ouyang WO, Liang W, Rivera-Cardona J, Teo C, Graham CS, Brooke CB, Presti RM, Mok CKP, Krammer F, Dai X, Ellebedy AH, Wu NC. Lei R, et al. Immunity. 2023 Nov 14;56(11):2621-2634.e6. doi: 10.1016/j.immuni.2023.10.005. Immunity. 2023. PMID: 37967533 Free PMC article. - Solution properties of Escherichia coli-expressed VH domain of anti-neuraminidase antibody NC41.
Kortt AA, Guthrie RE, Hinds MG, Power BE, Ivancic N, Caldwell JB, Gruen LC, Norton RS, Hudson PJ. Kortt AA, et al. J Protein Chem. 1995 Apr;14(3):167-78. doi: 10.1007/BF01980329. J Protein Chem. 1995. PMID: 7576085 - Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers.
Wan H, Yang H, Shore DA, Garten RJ, Couzens L, Gao J, Jiang L, Carney PJ, Villanueva J, Stevens J, Eichelberger MC. Wan H, et al. Nat Commun. 2015 Feb 10;6:6114. doi: 10.1038/ncomms7114. Nat Commun. 2015. PMID: 25668439 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases